Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Price Target of $6.67

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.67.

A number of brokerages recently commented on IPHA. UBS Group reiterated a “buy” rating on shares of Innate Pharma in a report on Tuesday, August 11th. Citigroup upgraded Innate Pharma from a “buy” rating to an “outperform” rating in a research note on Tuesday, August 11th. Leerink Partners upgraded shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research report on Tuesday, August 11th. HC Wainwright restated a “buy” rating on shares of Innate Pharma in a report on Monday, September 21st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Innate Pharma in a research report on Thursday, September 17th.

Innate Pharma Stock Performance

Shares of NASDAQ IPHA opened at $1.56 on Wednesday. Innate Pharma has a twelve month low of $1.17 and a twelve month high of $2.71. The stock’s 50 day moving average price is $1.96 and its 200-day moving average price is $1.75.

Innate Pharma Company Profile

Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.

Innate Pharma’s pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.